Neurocrine Biosciences (NBIX) Q4 2025 earnings review
The Torch Passes: CRENESSITY Sprints as INGREZZA Slows
Neurocrine delivered a solid beat, but the narrative has structurally shifted. The long-standing growth engine, INGREZZA, has decelerated significantly to single-digit growth (+7% YoY) due to pricing investments. However, the CRENESSITY launch is nothing short of spectacular, generating $135M in Q4 (vs. $98M in Q3) and driving total revenue up 29%. Management is effectively executing a pivot from a single-product story to a diversified portfolio, though FY26 guidance suggests the days of 20%+ aggregate top-line growth may be pausing as INGREZZA matures.
🐂 Bull Case
The CAH drug is outperforming even optimistic projections, growing 38% sequentially to $135.3M in Q4. With over 2,000 patient enrollment forms in 2025 and 80% reimbursement coverage, this is rapidly becoming a blockbuster-trajectory asset.
The company is no longer a one-trick pony. With Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia) advancing, and a new CRF platform for metabolic diseases, the R&D engine is finally diversifying risk.
🐻 Bear Case
The flagship product grew only 7% YoY in Q4, a stark contrast to the 23% growth seen a year ago. Management cites 'lower net price due to new formulary access,' confirming that volume gains are being eroded by gross-to-net pressure.
GAAP SG&A and R&D combined rose to $560M in Q4 from $473M a year ago. FY26 guidance implies continued heavy spending (Non-GAAP SG&A midpoint $1.25B), compressing margins as the company funds the CRENESSITY launch and pipeline.
⚖️ Verdict: 🟢
Bullish. While INGREZZA's deceleration is a concern, the sheer velocity of the CRENESSITY launch compensates for it. The company has successfully diversified its revenue base earlier than expected.
Key Themes
INGREZZA Deceleration
INGREZZA growth has officially slowed to a crawl. Q4 sales of $657.5M represented only 7% YoY growth, down from 12% in Q3 and 23% in the prior year. The driver is explicit: 'lower net price due to new formulary access investments.' While volume is growing double-digits, pricing power is fading faster than volume is adding up.
CRENESSITY Launch Execution
This is one of the best recent launches in the CNS/Endo space. Revenue ramped from $15M in Q1 to $135M in Q4. New patient start forms remain strong (431 in Q4), and reimbursement is high at 80%. This segment alone contributed nearly all of the sequential revenue growth for the company.
Strategic Pivot to Metabolic/Obesity
Management signaled a strategic expansion of their CRF platform into metabolic diseases, specifically obesity. This is a significant pivot from their pure-play neurology/psychiatry focus and represents a high-risk, high-reward expansion into a crowded but massive market.
Margin Compression via Reinvestment
Profitability is taking a backseat to pipeline expansion. GAAP Net Income margin was 19% in Q4 2025 vs 16% in Q4 2024, but operating expenses are surging. FY26 guidance calls for ~$2.3B in combined Non-GAAP R&D and SG&A (midpoint), which will weigh on earnings leverage despite top-line growth.
Pipeline entering 'Catalyst Rich' Phase
The R&D engine is humming. Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia) are active. The company is actively highlighting these as the next leg of growth, moving focus away from the maturing INGREZZA franchise.
Other KPIs
Strong balance sheet, up from $1.82B in Q4 2024. This provides ample firepower for BD or weathering the heavy R&D investment cycle.
Beat Q4 2024 ($1.69) by 11%. Driven by top-line beat in CRENESSITY, though partially offset by higher operating expenses.
Grew 21% YoY. The company has successfully crossed the mid-cap biotech valley of death and is scaling revenue efficiently.
Guidance
Decelerating. The midpoint ($2.75B) implies ~9.5% YoY growth vs FY25 ($2.51B). This confirms that single-digit growth is the new normal for the franchise as pricing headwinds persist.
Accelerating spending. Midpoint is ~$1.25B, representing a significant increase over FY25 ($1.02B). Driven by CRENESSITY launch support and sales force expansion.
Accelerating. Midpoint ($1.135B) is up ~23% vs FY25 ($925M). Reflects the cost of running multiple Phase 3 programs simultaneously.
Key Questions
CRENESSITY Peak Sales Trajectory
With the launch annualizing at over $540M already, have internal peak sales estimates shifted? Is the current pace driven by a backlog of warehoused patients, or is this organic demand sustainable?
INGREZZA Pricing Stabilization
Guidance implies ~9.5% growth. How much of this is volume vs price? Have the 'formulary access investments' fully played out in 2025, or should we expect further net price degradation in 2026?
Obesity Strategy Specifics
Regarding the CRF platform expansion into obesity: Is this an internal discovery play or are you looking for BD? How does NBIX differentiate in a GLP-1 dominated world?
DOJ Investigation Update
There was no specific update on the DOJ investigation mentioned in Q3. Has there been any change in the scope or status of the Civil Investigative Demand?